Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): In vitro and in vivo effects of genotoxic agents

Journal of Hepatology

Volumn 32, Issue 6, 2000, Pages 975-985

  Peng, Dacheng ^a   Qian, Cheng ^a,b   Sun, Yonglian ^a   Barajas, Miguel A ^a   Prieto, Jesus ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Div Hepatol Gene Ther Dept I   (Spain)

Author keywords

Animal model; Gene transfer; Liver cancer; Radiotherapy and chemotherapy; Vector

Indexed keywords

ETOPOSIDE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034085607     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80102-6     Document Type: Article

References (51)

1. Berns KI, Cheung A, Ostrove J, Lewis M. Adeno-associated virus latent infection. Mahy BWJ, Minson AC, Darby GK. Virus Persistence. 1982;249 Cambridge University Press, Cambridge.
2. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 63:1989;3822-3828.
3. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 70:1996;8098-8108.
4. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther. 8:1997;659-669.
5. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 3:1997;306-312.
6. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 5:1999;56-63.
7. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med. 5:1999;64-70.
8. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, et al. Direct intramuscular injection with recombinant-AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 5:1998;40-49.
9. Bachmann PA, Hoggan MD, Kurstak E. Parvoviridae: second report. Intervirology. 11:1979;248-254.
10. Flotte TR, Afione SA, Conrad C, Mcgrath SA, Solow R, Oka H, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA. 90:1993;10613-10617.
11. Flannery JG, Zolotukhin S, Vaquero MI, Lavail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:1997;6916-6921.
12. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4:1997;16-24.
13. Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virusmediated gene transfer into rat carotid arteries. Gene Ther. 4:1997;757-761.
14. Kessler PD, Podsakoff GM, Chen X, Mcquiston SA, Colosi PC, Matelis LA, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 93:1996;14082-14087.
15. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotech. 3:1992;533-539.
16. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Topics Microbiol. 158:1992;96-127.
17. Kotin R. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. 5:1994;793-801.
18. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. 2:1995;357-362.
19. Hallek M, Wendtner CM. Adeno-associated virus vectors for somatic gene therapy: recent advances and clinical applications. Cytokines Mol Ther. 2:1996;69-79.
20. Colombo M. Hepatocellular carcinoma. J Hepatol. 15:1995;225-236.
21. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 12:1994;1323-1334.
22. Su H, Lu R, Chang JC, Kan YW. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adenoassociated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc Natl Acad Sci USA. 94:1997;13891-13896.
23. Maass G, Bogedain C, Scheer U, Michl D, Horer M, Braun-Falco M, et al. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther. 9:1998;1049-1059.
24. Snyder RO, Miao CH, Ratijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 16:1997;270-276.
25. Alexander IE, Russell DW, Spence AM, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol. 68:1994;8282-8287.
26. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gene Ther. 7:1996;841-850.
27. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA. 92:1995;5719-5723.
28. Koeberl DD, Alexander IE, Halbert CL, Russell DW. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA. 94:1997;1426-1431.
29. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 61:1987;3096-3101.
30. Goodman S, Xiao X, Donahue RE, Moulton A, Miller J, Walsh C, et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood. 84:1994;1492-1500.
31. Qian C, Idoate M, Bilbao R, Sangro B, Bruña O, Vazques J, et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther. 8:1997;349-358.
32. Nolan GP, Fiering S, Nicolas JF, Herzenberg LA. Fluorescenceactivated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc Natl Acad Sci USA. 85:1988;2603-2607.
33. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol. 26:1967;365-369.
34. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 5:1998;189-195.
35. Farina P, Marzillo G, D'incalci M. High-performance liquid chromatography determination of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene β-D-glucopyranoside) (VP 16-213) in human plasma. J Chromatogr. 222:1981;141-145.
36. Harvey VJ, Joel SP. High-performance liquid chromatography of etoposide in plasma and urine. J Chromatogr. 339:1985;419-423.
37. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma: a comparison of VP-16 and adriamycin. Cancer. 51:1983;206-210.
38. Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EW, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 91:1998;4600-4607.
39. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 70:1996;520-532.
40. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 70:1996;3227-3234.
41. Msirikale JS, Klein JL, Schroeder J, Order SE. Radiation enhancement of radiolabelled antibody deposition on tumors. Ins J Radiat Oncol Biol Phys. 13:1987;1839-1844.
42. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res. 50:1990;159-163.
43. Buchegger F, Rojas A, Delaloye AB, Vogel CA, Mirimanoff RO, Coucke P, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res. 55:1995;83-89.
44. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK. Interstitial hypertension of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res. 51:1991;6695-6698.
45. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res. 56:1996;964-968.
46. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 81:1989;570-576.
47. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54:1994;4564-4568.
48. Curti BD. Physical barriers to drug delivery in tumors. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy. 1996;709-719 Lippincott-Raven Publishers, Philadelphia.
49. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nature Med. 4:1998;655-657.
50. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50:1990;4478-4484.
51. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 271:1994;58-65.